Portfolio Lab

Armata Pharmaceuticals, Inc.

  • Stock
  • Ticker ARMP
  • ISIN US04216R1023
  • NYSE

Health care · Biotechnology · USA

$3.03 +1.68%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Armata Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ARMPGlobal equities (VT)

$10,000 grew to $343. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −99.0% in 04/2025, measured from the peak in 11/2016. The old peak has not been reached again yet.

1-year return
−57.6%
5-year return p.a.
−5.0%
10-year return p.a.
−28.6%
Volatility p.a.
96.6%
Largest decline
−99.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Operating income-11-8.2-6.8-7.8-14-8.8-10-7.4
EBITDA-10-7.8-6.5-7.4-13-8.3-9.8-6.8
Net income2.6-6.5-16-27-124-1157455
Earnings per share-0.29-0.20-0.45-0.74-3.43-3.16-0.27-0.24
Balance sheet
Total assets8687819077709084
Liabilities134141150185295381321259
Equity-48-54-70-96-219-312-231-174
Cash9.3124.3158.74.82418
Cash flow
Operating cash flow-7.9-7.6-7.2-4.3-6.7-5.8-8.7-5.5
Capital expenditure0.1-0.1-0.1-0.2-0.1-0.10.0-0.1
Free cash flow-7.9-7.7-7.4-4.5-6.7-5.8-8.7-5.6

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +239.5%, weakest 2018 at −79.6%. 4 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
12 Nov 2026−$0.24
12 Aug 2026−$0.27
13 May 2026−$3.16
25 Mar 2026−$3.43
12 Nov 2025−$0.74
12 Aug 2025−$0.45
14 May 2025−$0.20
21 Mar 2025−$0.29
13 Nov 2024−$0.15
13 Aug 2024−$0.25
7 May 2024−$0.69
21 Mar 2024−$0.55

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€102m
Market cap in trading currency
$113m
Enterprise value
$94.4m
P/E
–
P/S
–
P/B
–
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-23.8%

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
−$38.3m
Net income
−$111m
Earnings per share
−$7.10
Revenue per share
–
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
–
Return on assets
-131.0%

Balance sheet and cash flow

Cash
$18.3m
Cash per share
$0.49
Financial debt
–
Debt/equity %
–
Current ratio
0.12
Book value per share
−$4.68
Operating cash flow
−$26.6m
Free cash flow
−$26.9m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
37.2m
Volume
85,636
Avg. volume 3 months
182,804
Relative volume
0.5

Price and technicals

Price
$3.03
1 day
+1.7%
52-week high
$14.80
52-week low
$2.66
Distance to 52-week high
−79.5%
Distance to 52-week low
+13.9%
Distance to 50-day line
−14.4%
Distance to 200-day line
−55.2%
RSI (14)
45
Volatility 1M
154.1%

Performance

1 week
−21.7%
1 month
−12.2%
3 months
−41.4%
6 months
−63.8%
YTD
−51.8%
1 year
−58.5%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ARMP performed since 11/2016?

$10,000 grew to $343 by 20 Nov 2026, which is −28.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ARMP?

Volatility was 96.6% per year, measured on monthly returns. The largest decline from a peak was −99.0%, with the low in 04/2025.

How does ARMP compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ARMP returned −28.6% at 96.6%. The correlation of monthly returns was 0.24; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.